[Pharmacological profile and clinical findings of a new phosphate binder, ferric citrate hydrate (Riona® Tablets)]

Nihon Yakurigaku Zasshi. 2014 Dec;144(6):294-304. doi: 10.1254/fpj.144.294.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Chelating Agents / adverse effects
  • Chelating Agents / pharmacology*
  • Chelating Agents / therapeutic use*
  • Clinical Trials as Topic
  • Ferric Compounds / adverse effects
  • Ferric Compounds / pharmacology*
  • Ferric Compounds / therapeutic use*
  • Ferritins / blood
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Hyperphosphatemia / drug therapy*
  • Hyperphosphatemia / etiology
  • Peritoneal Dialysis
  • Renal Dialysis
  • Renal Insufficiency, Chronic / complications
  • Tablets

Substances

  • Chelating Agents
  • Ferric Compounds
  • Tablets
  • ferric citrate
  • Ferritins